Taiko PharmaceuticalTAIKO PHARMACEUTICAL CO., LTD.4574東証プライム医薬品FY ending Dec 2025, consolidated, J-GAAP

Taiko Pharmaceutical FY ending Mar 2020 results

About 62% of Taiko Pharmaceutical's sales come from Infection Control Business, with Pharmaceuticals Business making up much of the rest.

Out of every ¥100 of sales, about ¥26 is left as operating profit.

Where the money goes

For every ¥100 Taiko Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 70.9% → Operating margin 25.6% → Net margin 16.4%

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Infection Control Business¥9.31B
62%
Op. margin 37.4%Industry: Toiletries & Household Products
Pharmaceuticals Business¥5.65B
38%
Op. margin 30.0%Industry: Pharmaceuticals

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第78期(2023/01/01－2023/12/31)
ID S100T5112024-03-28Open
EDINET (FSA Japan)
有価証券報告書－第76期(令和3年1月1日－令和3年12月31日)
ID S100NS202022-03-30Open
EDINET (FSA Japan)
有価証券報告書－第75期(令和2年4月1日－令和2年12月31日)
ID S100L2I22021-03-30Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.